866931 Stock Price and Chart — LS:866931

Key facts today

Novo Nordisk's weight-loss drug Wegovy launched in India this year, boosting awareness of obesity treatments. Sales of Wegovy and Eli Lilly's Mounjaro doubled shortly after their release.

Costco now sells a four-week supply of Novo Nordisk's weight-loss drugs, Ozempic and Wegovy, for $499 to members with a valid prescription, improving access.

In a mid-stage study, Novo Nordisk's semaglutide combined with Skye Bioscience's nimacimab led to a 13.2% average weight loss, surpassing the 10.25% from semaglutide alone.

Analyze the impact Analyze the impact

About Novo Nordisk A/S Class B

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Check out other big names from the same industry as 866931.